Verona Pharma Plc’s (VRP) “corporate” Rating Reiterated at N+1 Singer
Verona Pharma Plc (LON:VRP)‘s stock had its “corporate” rating reissued by N+1 Singer in a report issued on Tuesday.
VRP has been the topic of a number of other research reports. Jefferies Group LLC assumed coverage on shares of Verona Pharma Plc in a research note on Monday, May 22nd. They set a “buy” rating and a GBX 250 ($3.18) price target on the stock. Wedbush initiated coverage on shares of Verona Pharma Plc in a research note on Monday, May 22nd. They issued an “outperform” rating and a GBX 25 ($0.32) price objective on the stock. SunTrust Banks, Inc. initiated coverage on shares of Verona Pharma Plc in a research note on Monday, May 22nd. They issued a “buy” rating and a GBX 26 ($0.33) price objective on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Verona Pharma Plc in a research note on Monday, May 22nd. They issued a “buy” rating and a GBX 22 ($0.28) price objective on the stock. Four analysts have rated the stock with a buy rating, Verona Pharma Plc has a consensus rating of “Buy” and an average target price of GBX 80.75 ($1.03).
Shares of Verona Pharma Plc (LON:VRP) traded up 8.03% during mid-day trading on Tuesday, hitting GBX 128.56. 13,953 shares of the stock traded hands. Verona Pharma Plc has a one year low of GBX 120.77 and a one year high of GBX 210.00. The stock’s market cap is GBX 66.03 million. The stock has a 50-day moving average of GBX 135.72 and a 200 day moving average of GBX 144.66.
COPYRIGHT VIOLATION NOTICE: “Verona Pharma Plc’s (VRP) “corporate” Rating Reiterated at N+1 Singer” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/06/27/n1-singer-reaffirms-corporate-rating-for-verona-pharma-plc-vrp.html.
In other Verona Pharma Plc news, insider David Ebsworth acquired 177,776 shares of the business’s stock in a transaction dated Thursday, April 27th. The shares were purchased at an average price of GBX 169 ($2.15) per share, for a total transaction of £300,441.44 ($382,143.78).
About Verona Pharma Plc
Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
Receive News & Ratings for Verona Pharma Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma Plc and related companies with MarketBeat.com's FREE daily email newsletter.